Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
crinecerfont
Class :
Corticotropin-Releasing Factor Receptor Antagonist
Brand Name :
N/A
Synonyms :
crinecerfont
Class :
Corticotropin-Releasing Factor Receptor Antagonist
Adult
Congenital Adrenal Hyperplasia (CAH)
The drug is pending for FDA approval in treatment of classic congenital adrenal hyperplasia
Safety and efficacy are not established
CRF1 antagonist reduces cortisol, ACTH, and adrenal androgens through glucocorticoid-independent mechanisms.
No adverse reactions reported
None
None
Pregnancy category: N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
CAH causes 21-OHD deficiency to affect cortisol and aldosterone production.
It blocks CRF1 receptors in the pituitary lowers ACTH to decrease adrenal androgens and CAH symptoms.
Pharmacodynamics:
Not known
Pharmacokinetic:
ADME is not studied yet.
The route of administration is not known.
Generic Name: crinecerfont
Why do we use crinecerfont?
Crinecerfont an investigational drug pending for FDA approval works as a corticotropin-releasing factor type 1 receptor antagonist.
It is indicated in treatment of classic CAH disorder from 21-hydroxylase mutations in genetics.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
